Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG – Get Free Report)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $31.74, but opened at $29.15. Hemab Therapeutics shares last traded at $28.24, with a volume of 4,535 shares.
Analyst Ratings Changes
A number of brokerages recently issued reports on COAG. Wedbush assumed coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They issued an “outperform” rating and a $42.00 price objective on the stock. The Goldman Sachs Group started coverage on Hemab Therapeutics in a research note on Tuesday, May 26th. They set a “buy” rating and a $36.00 target price for the company. HC Wainwright began coverage on Hemab Therapeutics in a report on Wednesday, June 17th. They issued a “buy” rating and a $40.00 target price on the stock. Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th. Finally, Jefferies Financial Group started coverage on Hemab Therapeutics in a research note on Tuesday, May 26th. They issued a “buy” rating and a $39.00 price target on the stock. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $41.40.
Read Our Latest Report on Hemab Therapeutics
Hemab Therapeutics Stock Up 3.7%
Insider Activity at Hemab Therapeutics
In other news, major shareholder Ra Capital Management, L.P. acquired 61,523 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The stock was purchased at an average price of $24.98 per share, for a total transaction of $1,536,844.54. Following the completion of the acquisition, the insider directly owned 6,444,637 shares in the company, valued at $160,987,032.26. The trade was a 0.96% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. In the last three months, insiders bought 2,970,541 shares of company stock valued at $55,459,603.
Hemab Therapeutics Company Profile
Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.
Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.
Featured Stories
- Five stocks we like better than Hemab Therapeutics
- Dividend Increases: From Over 10% Yields to Over 10% Dividend Growth
- From Quantum to Clothing: Insider Trades Hit 3 Big Names
- ASML’s Chip Dominance Runs Into New Silicon Boundaries
- Why These South Korea-Focused ETFs Have More Than Doubled in 2026
Receive News & Ratings for Hemab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
